Please STOP IT!
Would someone please tell the folks on IHUB that the Request For Comments Confidentiality of Interim Results in Cardiovascular Outcome Safety Trials; Public Hearing; Request for Comments has nothing to do with REDUCE-IT.
They are not requesting input on whether it is appropriate to stop a trial like REDUCE-IT early if it achieves interim stopping rules.
They are requesting input on whether to release interim SAFETY data (and in what form) from trials assessing Cardiac SAFETY concerns (such SAFETY trials are required, for example, for drugs intended to treat T2DM).
Retail investors posting comments that display a lack of understanding of the distinction minimizes credibility when valid concerns are voiced (and Amarin investors have a LOT of valid issues to address w/the FDA, but this is NOT one of them).